NORTHLAND

NORTHLAND

Language

The Phase III clinical trial of recombinant human hepatocyte growth factor naked plasmid injection is progressing smoothly.

发布时间：2019-12-30

Since the Phase III clinical trial of “Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection,” initiated by our company, was officially launched in July, a total of nine research centers have been activated by year-end. Among these, 17 subjects have been screened, and 15 have been enrolled. Currently, the trial is proceeding smoothly according to schedule. This trial is jointly conducted by our company, Kun Tuo Xin Cheng Pharmaceutical R&D (Beijing) Co., Ltd. (a CRO), and Beijing Lianshida Pharmaceutical Technology Development Co., Ltd. (an SMO). The leading center is Peking Union Medical College Hospital, with Professor Changwei Liu from the Department of Vascular Surgery serving as the principal investigator. The trial is planned to be carried out at 20 centers nationwide. Following meticulous planning and careful preparation in the earlier stages, the project team has successfully completed...

27

2019-12

The results of the Phase II clinical study on recombinant human hepatocyte growth factor naked plasmid injection have been published in Molecular Therapy.

发布时间：2019-12-27

Recently, the results of the Phase II clinical study on “Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” (NL003), a gene therapy drug developed by our company, for the treatment of severe limb ischemia (CLI) were published in Volume 27, Issue 12 of Molecular Therapy (pages 2158–2165). This journal is sponsored by the American Society of Gene & Cell Therapy and primarily publishes groundbreaking research findings in the field of molecular therapy. Its 2018 impact factor was 8.402. The study employed a randomized, double-blind, multicenter, placebo-controlled design, with a total of 2 patients randomly enrolled across nine research centers in China.

23

2019-12

Our company has signed a design agreement with South Korea’s GCEM for the construction of a biopharmaceutical production facility.

发布时间：2019-12-23

On December 19, 2019, Xu Songshan, Chairman of the company, and Park, Chung-Gwon, General Manager of South Korea’s GCEM, signed a project design agreement at the headquarters of Green Cross Corporation in South Korea. GCEM will undertake the design work for the second phase of NORTHLAND’s industrialization base—the “Biopharmaceutical Production Base.” The primary function of the “Biopharmaceutical Production Base” is to support the industrial-scale production of innovative drugs developed by the company. The project is planned to cover a construction area of 38,000 square meters and is expected to be completed in 2022. The construction scope includes a bulk drug substance production workshop, a formulation production workshop, a CMO production workshop, a pilot-scale workshop, and R&D...

13

2019-12

Holding subsidiary Huonland and Ocumetics have signed a strategic cooperation agreement in the ophthalmology field.

发布时间：2019-12-13

On December 12, 2019, Beijing Huonland Pharmaceutical Co., Ltd. and Ocumetics Biopharmaceutical (Shanghai) Co., Ltd. signed a strategic cooperation agreement on ophthalmology in Beijing. The two parties will initially collaborate on a single-dose sodium hyaluronate eye drop product (0.3%). Huonland will be responsible for the production and quality control of this product, while Ocumetics will handle its exclusive promotion nationwide. Chairman Xu Songshan, General Manager Nie Liya, Ocumetics CEO Liu Ye, and other senior leaders from both companies witnessed the signing ceremony. Chairman Xu Songshan stated: “Huonland is a specialized manufacturer of ophthalmic pharmaceutical products and boasts advanced...”

19

2019-11

The discussion meeting on the Phase II clinical trial protocol for Recombinant Human Thymosin β4 for Injection (NL005) was successfully held.

发布时间：2019-11-19

On November 18, 2019, our company successfully held a meeting at the Beijing Guobin Hotel to discuss the Phase IIa clinical trial protocol for recombinant human thymosin β4 for injection (NL005). The purpose of the meeting was to develop a scientifically sound and reasonable clinical trial protocol, and it achieved the expected results. The meeting was chaired by Professor Dou Kefei, Deputy Director of the Coronary Heart Disease Center at Fuwai Hospital, Chinese Academy of Medical Sciences. Guests at the meeting included Professor Li Jing, Chief Physician of the Department of Cardiology/PCI Team at Xuanwu Hospital, Capital Medical University; Professor Guo Jincheng, Director of the Cardiovascular Center and CCU Director at Beijing Luhe Hospital Affiliated to Capital Medical University; and representatives from the Coronary Heart Disease Center at Fuwai Hospital, Chinese Academy of Medical Sciences.

19

2019-08

The investigator meeting for the Phase III clinical trial of “Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” was successfully held.

发布时间：2019-08-19

On August 18, 2019, the investigator meeting for the Phase III clinical trial of "Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection," hosted by Beijing Northland Biotechnology Co., Ltd., was successfully held in Beijing. More than 80 participants attended the meeting, including medical experts from the leading center, Peking Union Medical College Hospital, and nearly 20 research centers nationwide, as well as representatives from third-party research organizations such as Kuntexin Cheng, Liansida, and Taimai Medical. The meeting was chaired by Professor Changwei Liu, the principal investigator of the Phase III clinical trial from the Department of Vascular Surgery at Peking Union Medical College Hospital. Professor Liu focused on the selection and design of drug injection sites; NORTHLAND medical staff provided an introduction.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

Follow Us

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

WeChat Mini Program

Web site

WeChat Official Account

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license

Powered by 300.cn  Privacy Policy